FibroGen, Inc (FGEN): Price and Financial Metrics


FibroGen, Inc (FGEN): $10.80

0.06 (+0.56%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

FGEN POWR Grades


  • FGEN scores best on the Quality dimension, with a Quality rank ahead of 75.96% of US stocks.
  • The strongest trend for FGEN is in Momentum, which has been heading down over the past 48 weeks.
  • FGEN's current lowest rank is in the Sentiment metric (where it is better than 0.75% of US stocks).

FGEN Stock Summary

  • Of note is the ratio of Fibrogen Inc's sales and general administrative expense to its total operating expenses; merely 6.01% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 134.22%, Fibrogen Inc's debt growth rate surpasses 93.28% of about US stocks.
  • The volatility of Fibrogen Inc's share price is greater than that of 97.88% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to FGEN, based on their financial statements, market capitalization, and price volatility, are XNCR, NKTR, FATE, ATRA, and RAPT.
  • Visit FGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.fibrogen.com.

FGEN Valuation Summary

  • In comparison to the median Healthcare stock, FGEN's price/sales ratio is 44.49% lower, now standing at 6.3.
  • FGEN's EV/EBIT ratio has moved up 43.1 over the prior 83 months.
  • Over the past 83 months, FGEN's price/earnings ratio has gone up 29.6.

Below are key valuation metrics over time for FGEN.

Stock Date P/S P/B P/E EV/EBIT
FGEN 2021-08-31 6.3 4.1 -4.7 -3.6
FGEN 2021-08-30 6.2 4.1 -4.6 -3.6
FGEN 2021-08-27 6.2 4.1 -4.6 -3.6
FGEN 2021-08-26 6.2 4.1 -4.6 -3.5
FGEN 2021-08-25 6.4 4.2 -4.8 -3.7
FGEN 2021-08-24 6.5 4.3 -4.8 -3.8

FGEN Growth Metrics

  • Its 3 year net income to common stockholders growth rate is now at -34.47%.
  • Its 4 year cash and equivalents growth rate is now at -17.98%.
  • The 4 year revenue growth rate now stands at 33.35%.
FGEN's revenue has moved down $6,361,000 over the prior 52 months.

The table below shows FGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 171.824 -80.104 -231.373
2021-03-31 190.348 96.104 -182.698
2020-12-31 176.319 81.602 -189.291
2020-09-30 119.295 43.78 -228.78
2020-06-30 108.437 17.646 -311.223
2020-03-31 257.115 -160.671 -109.907

FGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FGEN has a Quality Grade of B, ranking ahead of 75.49% of graded US stocks.
  • FGEN's asset turnover comes in at 0.212 -- ranking 194th of 677 Pharmaceutical Products stocks.
  • MNKKQ, CKPT, and ARWR are the stocks whose asset turnover ratios are most correlated with FGEN.

The table below shows FGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.212 0.934 -1.182
2021-03-31 0.235 0.941 -0.907
2020-12-31 0.216 0.950 -0.594
2020-09-30 0.145 0.940 -0.473
2020-06-30 0.128 0.952 -0.520
2020-03-31 0.295 0.992 -0.151

FGEN Price Target

For more insight on analysts targets of FGEN, see our FGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.71 Average Broker Recommendation 1.95 (Hold)

FGEN Stock Price Chart Interactive Chart >

Price chart for FGEN

FGEN Price/Volume Stats

Current price $10.80 52-week high $57.21
Prev. close $10.74 52-week low $9.89
Day low $10.60 Volume 806,900
Day high $10.90 Avg. volume 1,381,071
50-day MA $12.40 Dividend yield N/A
200-day MA $27.97 Market Cap 1.00B

FibroGen, Inc (FGEN) Company Bio


Fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is based in San Francisco, California.


FGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

FGEN Latest Social Stream


Loading social stream, please wait...

View Full FGEN Social Stream

Latest FGEN News From Around the Web

Below are the latest news stories about Fibrogen Inc that investors may wish to consider to help them evaluate FGEN as an investment opportunity.

Why FibroGen Fell by More Than 9% on Wednesday

The rising stock market had many winners on Wednesday, but alas for its shareholders FibroGen (NASDAQ: FGEN) wasn't one of them. Goldman Sachs analyst Paul Choi has downshifted his recommendation for FibroGen stock. Choi's concern is the company's leading product, roxadustat, which targets anemia due to chronic kidney disease.

Yahoo | September 22, 2021

Fibrogen Inc (FGEN): Price Now Near $11.74; Daily Chart Shows Downtrend on 100 Day Basis

Regarding the trend, note that the strongest trend exists on the 50 hour timeframe. The post Fibrogen Inc (FGEN): Price Now Near $11.74; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News .

ETF Daily News | September 13, 2021

Idiopathic Pulmonary Fibrosis Market 2021-2030: Exceptional Business Performance | Boehringer Ingelheim Pharma GmbH, and Co. Kg, MediciNova, FibroGen, Inc.

Global Idiopathic Pulmonary Fibrosis Market Report published by Astute Analytica provides insight and updates about the corresponding segments involved in the global market for the forecast period of 2021-2030. A detailed analysis of the market dynamics is provided and comprehensive

OpenPR | September 9, 2021

Trade Alert: The Chief Commercial Officer Of FibroGen, Inc. (NASDAQ:FGEN), Thane Wettig, Has Just Spent US$36k Buying 46% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the FibroGen, Inc. ( NASDAQ:FGEN ) Chief...

Yahoo | September 3, 2021

Global Idiopathic Pulmonary Fibrosis (IPF) Market Analysis, Scope Significant Demand Foreseen by 2021-27 Market I Major key players-Biogen, Inc , Boehringer Ingelheim Gmbh , Bristol-Myers Squibb Company , Cipla Inc , F. Hoffmann-La Roche Ag , Fibrogen, In

The study examines the global idiopathic pulmonary fibrosis market in detail, including current trends and forecasts, in order to identify potential investment opportunities. Idiopathic pulmonary fibrosis is an interstitial lung disease in which the lung tissues are destroyed, limiting the

OpenPR | September 2, 2021

Read More 'FGEN' Stories Here

FGEN Price Returns

1-mo -6.49%
3-mo -60.01%
6-mo -68.89%
1-year -74.45%
3-year -82.22%
5-year -51.02%
YTD -70.88%
2020 -13.52%
2019 -7.32%
2018 -2.36%
2017 121.50%
2016 -29.77%

Continue Researching FGEN

Here are a few links from around the web to help you further your research on Fibrogen Inc's stock as an investment opportunity:

Fibrogen Inc (FGEN) Stock Price | Nasdaq
Fibrogen Inc (FGEN) Stock Quote, History and News - Yahoo Finance
Fibrogen Inc (FGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8933 seconds.